Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the drug susceptibility of 2009 pandemic influenza A (H1N1) viruses collected globally between April 2009 and January 2010.
Methods
Virus isolates were tested for adamantane susceptibility, using pyrosequencing to detect the S31N marker of adamantane resistance in the M2 protein and biological assays to assess viral replication in cell culture. To assess neuraminidase (NA) inhibitor (NAI) susceptibility, virus isolates were tested in chemiluminescent NA inhibition assays and by pyrosequencing to detect the H275Y (H274Y in N2 numbering) marker of oseltamivir resistance in the NA.
Results
With the exception of three, all viruses that were tested for adamantane susceptibility (n=3,362) were resistant to this class of drugs. All viruses tested for NAI susceptibility (n=3,359) were sensitive to two US Food and Drug Administration-approved NAIs, oseltamivir (mean ±sd 50% inhibitory concentration [IC50] 0.25 ±0.12 nM) and zanamivir (mean IC50 0.29 ±0.09 nM), except 23 (0.7%), which were resistant to oseltamivir, but sensitive to zanamivir. Oseltamivir-resistant viruses had the H275Y mutation in their NA and were detected in patients exposed to the drug through prophylaxis or treatment. NA activity of all viruses was inhibited by the NAIs peramivir, laninamivir (R-125489) and A-315675, except for H275Y variants, which exhibited approximately 100-fold reduction in peramivir susceptibility.
Conclusions
This report provides data regarding antiviral susceptibility of 2009 pandemic influenza A (H1N1) surveillance viruses, the majority of which were resistant to adamantanes and sensitive to NAIs. These findings provide information essential for antiviral resistance monitoring and development of novel diagnostic tests for detecting influenza antiviral resistance.
References
1.
Centers for Disease Control and Prevention.Update: swine influenza A (H1N1) infections – California and Texas, April 2009.MMWR Morb Mortal Wkly Rep2009; 58: 435–437.
2.
Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team.Emergence of a novel swine-origin influenza A (H1N1) virus in humans.N Engl J Med2009; 360: 2605–2615.
3.
GartenR.J., DavisC.T., RussellC.A.Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans.Science2009; 325: 197–201.
4.
Centers for Disease Control and Prevention.Update on influenza A (H1N1) 2009 monovalent vaccines.MMWR Morb Mortal Wkly Rep2009; 58: 1100–1101.
5.
SmithG.J., VijaykrishnaD., BahlJ.Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic.Nature2009; 459: 1122–1125.
6.
Centers for Disease Control and Prevention.Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.MMWR Morb Mortal Wkly Rep2009; 58: 433–435.
7.
ItohY., ShinyaK., KisoM.In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses.Nature2009; 460: 1021–1025.
8.
DeydeV.M., SheuT.G., TrujilloA.A.Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing.Antimicrob Agents Chemother2010; 54: 1102–1110.
9.
SheuT.G., DeydeV.M., Okomo-AdhiamboM.Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.Antimicrob Agents Chemother2008; 52: 3284–3292.
10.
BuxtonR.C., EdwardsB., JuoR.R., VoytaJ.C., TisdaleM., BethellR.C.Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.Anal Biochem2000; 280: 291–300.
11.
MontoA.S., McKimm-BreschkinJ.L., MackenC.Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use.Antimicrob Agents Chemother2006; 50: 2395–2402.
12.
DeydeV., GartenR., SheuT.Genomic events underlying the changes in adamantane resistance among influenza A(H3N2) viruses during 2006–2008.Influenza Other Respi Viruses2009; 3: 297–314.
13.
PielakR.M., SchnellJ.R., ChouJ.J.Mechanism of drug inhibition and drug resistance of influenza A M2 channel.Proc Natl Acad Sci U S A2009; 106: 7379–7384.
14.
DuQ.S., HuangR.B., WangC.H., LiX.M., ChouK.C.Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus.J Theor Biol2009; 259: 159–164.
15.
TominackR.L., HaydenF.G.Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections.Infect Dis Clin North Am1987; 1: 459–478.
16.
HaydenF.G., BelsheR.B., CloverR.D., HayA.J., OakesM.G., SooW.Emergence and apparent transmission of rimantadine-resistant influenza A virus in families.N Engl J Med1989; 321: 1696–1702.
PotierM., MameliL., BelisleM., DallaireL., MelanconS.B.Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-d-N-acetylneuraminate) substrate.Anal Biochem1979; 94: 287–296.
19.
RussellR.J., HaireL.F., StevensD.J.The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.Nature2006; 443: 45–49.
20.
LuoM.Structural biology: antiviral drugs fit for a purpose.Nature2006; 443: 37–38.
21.
McKimm-BreschkinJ., TrivediT., HampsonA.Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.Antimicrob Agents Chemother2003; 47: 2264–2272.
22.
DeydeV.M., GubarevaL.V.Influenza genome analysis using pyrosequencing method: current applications for a moving target.Expert Rev Mol Diagn2009; 9: 493–509.
23.
TisdaleM.Monitoring of viral susceptibility: new challenges with the development of influenza NA inhibitors.Rev Med Virol2000; 10: 45–55.
24.
HayA.J., ZambonM.C., WolstenholmeA.J., SkehelJ.J., SmithM.H.Molecular basis of resistance of influenza A viruses to amantadine.J Antimicrob Chemother1986; 18 Suppl B: 19–29.
25.
BrightR.A., MedinaM.J., XuX.Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern.Lancet2005; 366: 1175–1181.
26.
DeydeV.M., XuX., BrightR.A.Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide.J Infect Dis2007; 196: 249–257.
27.
KrumbholzA., SchmidtkeM., BergmannS.High prevalence of amantadine resistance among circulating European porcine influenza A viruses.J Gen Virol2009; 90: 900–908.
28.
SchmidtkeM., ZellR., BauerK.Amantadine resistance among porcine H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany between 1981 and 2001.Intervirology2006; 49: 286–293.
29.
HeG., QiaoJ., DongC., HeC., ZhaoL., TianY.Amantadine-resistance among H5N1 avian influenza viruses isolated in Northern China.Antiviral Res2008; 77: 72–76.
30.
CheungC.L., RaynerJ.M., SmithG.J.Distribution of amantadine-resistant H5N1 avian influenza variants in Asia.J Infect Dis2006; 193: 1626–1629.
31.
BrightR.A., ShayD.K., ShuB., CoxN.J., KlimovA.I.Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States.JAMA2006; 295: 891–894.
32.
ZoidisG., FytasC., PapanastasiouI.Heterocyclic rimantadine analogues with antiviral activity.Bioorg Med Chem2006; 14: 3341–3348.
33.
De ClercqE.Antiviral agents active against influenza A viruses.Nat Rev Drug Discov2006; 5: 1015–1025.
34.
MosconaA.Medical management of influenza infection.Annu Rev Med2008; 59: 397–413.
35.
BarrosoL., TreanorJ., GubarevaL., HaydenF.G.Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment.Antivir Ther2005; 10: 901–910.
36.
BantiaS., ArnoldC.S., ParkerC.D., UpshawR., ChandP.Anti-influenza virus activity of peramivir in mice with single intramuscular injection.Antiviral Res2006; 69: 39–45.
37.
BoltzD.A., RehgJ.E., McClarenJ., WebsterR.G., GovorkovaE.A.Oseltamivir prophylactic regimens prevent H5N1 influenza morbidity and mortality in a ferret model.J Infect Dis2008; 197: 1315–1323.
38.
YunN.E., LindeN.S., ZacksM.A.Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/ Vietnam/1203/04 (H5N1).Virology2008; 374: 198–209.
39.
Centers for Disease Control and Prevention.Termination of the Emergency Use Authorization (EUA) of Medical Products and Devices. (Updated 24 June 2010. Accessed 23 September 2010.) Available from http://www.cdc.gov/h1n1flu/eua/peramivir.htm.
40.
CastilloR., HollandL.E., BoltzD.A.Peramivir and its use in H1N1 influenza.Drugs Today (Barc)2010; 46: 399–408.
41.
MemoliM.J., HrabalR.J., HassantoufighiA.Rapid selection of oseltamivir and peramivir resistant pandemic H1N1 during therapy in two immunocompromised hosts.Clin Infect Dis2010; 50: 1252–1255.
42.
BabuY.S., ChandP., BantiaS.BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.J Med Chem2000; 43: 3482–3486.
43.
WangM.Z., TaiC.Y., MendelD.B.Mechanism by which mutations at his274 alter sensitivity of influenza a virus N1 neuraminidase to oseltamivir carboxylate and zanamivir.Antimicrob Agents Chemother2002; 46: 3809–3816.
44.
YamashitaM., TomozawaT., KakutaM., TokumitsuA., NasuH., KuboS.CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.Antimicrob Agents Chemother2009; 53: 186–192.
45.
KoyamaK., TakahashiM., OitateM.CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long retention profile in the mouse respiratory tract.Antimicrob Agents Chemother2009; 53: 4845–4851.
46.
MacdonaldS.J., WatsonK.G., CameronR.Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen.Antimicrob Agents Chemother2004; 48: 4542–4549.
47.
MacdonaldS.J., CameronR., DemaineD.A.Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.J Med Chem2005; 48: 2964–2971.
48.
SugayaN., OhashiY.Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.Antimicrob Agents Chemother2010; 54: 2575–2582.
49.
AbedY., NehmeB., BazM., BoivinG.Activity of the neuraminidase inhibitor A-315675 against oseltamivir-resistant influenza neuraminidases of N1 and N2 subtypes.Antiviral Res2008; 77: 163–166.
50.
IsonM.G., MishinV.P., BracialeT.J., HaydenF.G., GubarevaL.V.Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection.J Infect Dis2006; 193: 765–772.
51.
MishinV.P., HaydenF.G., GubarevaL.V.Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.Antimicrob Agents Chemother2005; 49: 4515–4520.
52.
HurtA.C., HolienJ.K., ParkerM., KelsoA., BarrI.G.Zanamivir-resistant influenza viruses with a novel neuraminidase mutation.J Virol2009; 83: 10366–10373.
53.
Okomo-AdhiamboM., NguyenH.T., SleemanK.Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A (H1N1) viruses.Antiviral Res2010; 85: 381–388.
54.
Centers for Disease Control and Prevention.Flu review. 2009–2010 influenza season week 20 ending May 22, 2010. (Updated 28 May 2010. Accessed 23 September 2010.) Available from http://www.cdc.gov/flu/weekly.
